Sebacia is a clinical- and commercial-stage dermatology and aesthetics company based in Duluth, Ga., developing a proprietary microparticle treatment for moderate to severe acne delivered in a topical suspension that works with existing hair-removal and pigmented-lesion laser systems. The treatment is intended as a physician-guided, in-office procedure that could serve as an alternative to oral antibiotics and isotretinoin. Sebacia reports nearly 2,000 treatments performed to date, the procedure is CE Marked in Europe, and it is being evaluated in U.S. clinical studies. The company intends to use the financing to complete a U.S. pivotal trial with expected results by mid-2018 and to submit to the FDA with a response expected by the end of 2018. Proceeds will also support expansion of its commercial presence in the European Union and strengthening its worldwide patent estate, which includes selective photothermalysis methods developed by Dr. R. Rox Anderson at Massachusetts General Hospital. The company is led by CEO Anthony V. Lando. Sebacia develops the Sebacia Treatment, which uses proprietary Sebacia Gold Microparticles in combination with hair‑removal lasers to reduce acne during in‑office dermatology treatments. The technology has demonstrated efficacy in two clinical studies. The company is led by CEO Anthony Lando and recently named Pedro Medrano as Vice President, Engineering and Program Management. Sebacia plans to complete a pivotal U.S. clinical trial and submit an application to the U.S. FDA to register the device for treatment of moderate to severe acne. It also intends to expand its intellectual property portfolio and prepare for manufacturing scale‑up to support European and U.S. product launches. The company completed a $22M Series C financing to fund these next steps.

Total raised

$58M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Jul 2017